Kristin B Hendricks

US Patent:

7462697, Dec 9, 2008

Filed:

Nov 8, 2004

Appl. No.:

10/984473

Inventors:

Fernando Jose Rebelo Do Couto - Pleasanton CA, US
Kristin B. Hendricks - San Carlos CA, US
S. Ellen Wallace - Sunnyvale CA, US
Guo-Liang Yu - Berkeley CA, US

Assignee:

Epitomics, Inc. - Burlingame CA

International Classification:

C12P 21/08
A61K 39/00
G01N 33/53

US Classification:

5303873, 4241331, 435 71

Abstract:

The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.

US Patent:

7959921, Jun 14, 2011

Filed:

Aug 21, 2008

Appl. No.:

12/196200

Inventors:

Fernando Jose Rebelo Do Couto - Pleasanton CA, US
Kristin Beth Hendricks - San Carlos CA, US
Stacey Ellen Wallace - Sunnyvale CA, US

Assignee:

Epitomics, Inc. - Burlingame CA

International Classification:

A61K 39/395

US Classification:

4241451

Abstract:

The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.

US Patent:

7960517, Jun 14, 2011

Filed:

Oct 31, 2008

Appl. No.:

12/263002

Inventors:

Fernando Jose Rebelo Do Couto - Pleasanton CA, US
Kristin B. Hendricks - San Carlos CA, US
S. Ellen Wallace - Sunnyvale CA, US
Guo-Liang Yu - Berkeley CA, US

Assignee:

Epotimics, Inc. - Burlingame CA

International Classification:

C12P 21/08
A61K 39/00
G01N 33/53

US Classification:

5303873, 5303871, 4241331, 435 71

Abstract:

The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.

US Patent:

8211433, Jul 3, 2012

Filed:

Apr 29, 2011

Appl. No.:

13/098233

Inventors:

Fernando Jose Rebelo Do Couto - Pleasanton CA, US
Kristin Beth Hendricks - San Carlos CA, US
Stacey Ellen Wallace - Sunnyvale CA, US

Assignee:

Epitomics, Inc. - Burlingame CA

International Classification:

A61K 39/395

US Classification:

4241451

Abstract:

The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.

US Patent:

8404816, Mar 26, 2013

Filed:

May 3, 2011

Appl. No.:

13/100089

Inventors:

Fernando Jose Rebelo Do Couto - Pleasanton CA, US
Kristin B. Hendricks - San Carlos CA, US
S. Ellen Wallace - Sunnyvale CA, US
Guo-Liang Yu - Hillsborough CA, US

Assignee:

Epitomics, Inc. - Burlingame CA

International Classification:

C12P 21/08
A61K 39/00
G01N 33/53

US Classification:

5303873, 5303871, 4241331, 435 71

Abstract:

The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.

US Patent:

8444984, May 21, 2013

Filed:

Jun 7, 2012

Appl. No.:

13/491239

Inventors:

Fernando Jose Rebelo Do Couto - Pleasanton CA, US
Kristin Beth Hendricks - San Carlos CA, US
Stacey Ellen Wallace - Sunnyvale CA, US

Assignee:

Epitomics, Inc. - Burlingame CA

International Classification:

A61K 39/395

US Classification:

4241451, 4241331, 4241351, 4241781

Abstract:

The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.

US Patent:

20060216293, Sep 28, 2006

Filed:

Mar 24, 2005

Appl. No.:

11/090105

Inventors:

Fernando Couto - Pleasanton CA, US
Kristin Hendricks - San Carlos CA, US
Stacey Wallace - Sunnyvale CA, US

International Classification:

A61K 39/395
C07K 16/24

US Classification:

424145100, 530388230

Abstract:

The invention provides monoclonal antibodies that neutralize TNα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.

US Patent:

20120329069, Dec 27, 2012

Filed:

Aug 10, 2012

Appl. No.:

13/572239

Inventors:

Fernando Jose Rebelo Do Couto - Pleasanton CA, US
Kristin B. Hendricks - San Carlos CA, US
S. Ellen Wallace - Sunnyvale CA, US
Guo-Liang Yu - Hillsborough CA, US

International Classification:

C07K 16/00
C12P 21/00
G01N 33/53

US Classification:

435 72, 436501, 435 792, 435 696, 5303873

Abstract:

The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.